% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, AŞ Message Board

  • ahhaha2 ahhaha2 Nov 3, 2012 12:23 AM Flag

    The CC, Q&A, Deutsche Banc

    Robyn Karnauskas - Deutsche Bank AG, Research Division

    Just quickly on oprozomib. Maybe you could give us some thoughts on whether or not you think you'll be able to quickly progress from Phase I to Phase III like Millennium and maybe potential timelines? And second, are insurers for Kyprolis requesting any proof of progression on Del Rev or progression within 60 days?


    Okay. I think with regards to the oprozomib question, Barb, I'd ask you to give you some color commentary.

    Barbara Klencke

    So our current ongoing study is the Phase I/II, which means that our intent is to do the dose finding with dose escalation to maximum tolerated dose, identify the optimal dosing schedule, and then to expand in Phase II as efficiently as we can utilizing that same study. So our current plan is Phase I, Phase II before we move into Phase III.



    Helen I. Torley

    And with regard to the coverage policies for Kyprolis, where there are prior authorizations in place or they're asking for additional documentation, that generally is taking the form of a simple form where the physician is asked to affirm that the patient has previously received bortezomib and an IMiD and is now progressing. So the physician just affirms that and, obviously, has the documentation in their case records to indicate that's the case.